



## **Cyxone's presentation at BioStock Life Science Summit 18 November now published**

Cyxone's CEO Tara Heitner presented the company at BioStock Life Science Summit on 18 November 2020. [Click here to see the video.](#)

### **Contact**

Tara Heitner, CEO  
Tel: +46 70 781 88 08  
Email: [tara.heitner@cyxone.com](mailto:tara.heitner@cyxone.com)  
Adelgatan 21  
211 22 Malmö, Sweden

### **About Cyxone**

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is Mangold Fondkommission AB, +46 (0)8 503 015 50, [ca@mangold.se](mailto:ca@mangold.se). For more information, please visit [www.cyxone.com](http://www.cyxone.com)